point well taken. I too am skeptical whenever MOA of drugs are not clear, and was also dubious in this case in particular since inhibiting polymerase, in and of itself, shouldn't have an effect on *existing* cccDNA based on the HBV life cycle. that said, there was curious data from the prior trial, and happy accidents have occurred in drug development
Market Data 
Markets 
AI
